This article examines the comparator arm drug access and reimbursement policies in Canada to help sponsors make more informed trial expansion decisions. Despite the fact that Canada has some strong cards to play as a region for the expansion of both early and late phase oncology trials, sponsors from the United States may have reservations simply because they are unfamiliar with the region’s drug availability and reimbursement landscape.

Download the article for an explanation of the process in what is a dynamic and sometimes complex regulatory environment.

Be sure to Join the discussion in the Optimizing Oncology Clinical Research group on LinkedIn.